OTCMKTS:DMCAF DiaMedica Therapeutics - DMCAF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.59 +0.08 (+5.30%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.47▼$1.5950-Day Range$1.35▼$1.8952-Week Range$0.38▼$0.38Volume15,843 shsAverage Volume131,151 shsMarket Capitalization$249.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlines About DiaMedica Therapeutics (OTCMKTS:DMCAF) StockDiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More Receive DMCAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DMCAF Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comDiaMedica Therapeutics (OTCMKTS:DMCAF) Trading 6.2% Higher November 2, 2022 | msn.comWhat Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy StockMarch 27, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastAugust 12, 2022 | seekingalpha.comDiamedica Therapeutics GAAP EPS of -$0.13August 11, 2022 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call TranscriptOctober 30, 2019 | www.bloomberg.comDiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in CJune 20, 2019 | feeds.benzinga.comWhat's Pushing Nano-Cap Biotech DiaMedica's Shares Higher?May 14, 2019 | seekingalpha.comDiaMedica Therapeutics Inc. (DMCAF) CEO Rick Pauls on Q1 2019 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DMCAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:DMCAF CUSIPN/A CIKN/A Webwww.diamedica.com Phone763-496-5454FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares157,140,000Free FloatN/AMarket Cap$249.85 million OptionableNot Optionable Beta-0.02 Key ExecutivesMr. Rick Pauls MBA (Age 47)CEO, Pres & Director Dr. Todd A. Verdoorn Ph.D.Chief Scientific OfficerMr. Scott B. Kellen (Age 53)CFO & Company Sec. Mr. Edward B. Rady (Age 69)Chief Commercial Advisor Dr. Dennis D. Kim M.D. (Age 48)MBA, Consulting Chief Medical Officer Key CompetitorsKezar Life SciencesNASDAQ:KZRActinium PharmaceuticalsNYSEAMERICAN:ATNMGeneration BioNASDAQ:GBIOImmuneeringNASDAQ:IMRXRigel PharmaceuticalsNASDAQ:RIGLView All Competitors DMCAF Stock - Frequently Asked Questions How have DMCAF shares performed in 2023? DiaMedica Therapeutics' stock was trading at $1.5801 at the start of the year. Since then, DMCAF stock has increased by 0.6% and is now trading at $1.59. View the best growth stocks for 2023 here. What is DiaMedica Therapeutics' stock symbol? DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF." How do I buy shares of DiaMedica Therapeutics? Shares of DMCAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DiaMedica Therapeutics' stock price today? One share of DMCAF stock can currently be purchased for approximately $1.59. How much money does DiaMedica Therapeutics make? DiaMedica Therapeutics (OTCMKTS:DMCAF) has a market capitalization of $249.85 million. How can I contact DiaMedica Therapeutics? DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at 763-496-5454 or via email at ppapi@diamedica.com. This page (OTCMKTS:DMCAF) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.